Back to Search
Start Over
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
- Source :
- Blood Cancer Journal, Dipòsit Digital de Documents de la UAB, Universitat Autònoma de Barcelona, Scientia, Digital.CSIC. Repositorio Institucional del CSIC, instname, r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol, Blood Cancer Journal, Vol 10, Iss 10, Pp 1-10 (2020)
- Publication Year :
- 2020
-
Abstract
- © The Author(s) 2020.<br />Detecting persistent minimal residual disease (MRD) allows the identification of patients with an increased risk of relapse and death. In this study, we have evaluated MRD 3 months after transplantation in 106 myeloma patients using a commercial next-generation sequencing (NGS) strategy (LymphoTrack®), and compared the results with nextgeneration flow (NGF, EuroFlow). The use of different marrow pulls and the need of concentrating samples for NGS biased the applicability for MRD evaluation and favored NGF. Despite that, correlation between NGS and NGF was high (R2 = 0.905). The 3-year progression-free survival (PFS) rates by NGS and NGF were longer for undetectable vs. positive patients (NGS: 88.7% vs. 56.6%; NGF: 91.4% vs. 50%; p < 0.001 for both comparisons), which resulted in a 3-year overall survival (OS) advantage (NGS: 96.2% vs. 77.3%; NGF: 96.6% vs. 74.9%, p < 0.01 for both comparisons). In the Cox regression model, NGS and NGF negativity had similar results but favoring the latter in PFS (HR: 0.20, 95% CI: 0.09–0.45, p < 0.001) and OS (HR: 0.21, 95% CI: 0.06–0.75, p = 0.02). All these results reinforce the role of MRD detection by different strategies in patient prognosis and highlight the use of MRD as an endpoint for multiple myeloma treatment.
- Subjects :
- Adult
Male
Oncology
medicine.medical_specialty
Nucleòtids - Anàlisi
Neoplasm, Residual
Myeloma
lcsh:RC254-282
Disease-Free Survival
Article
DNA sequencing
EuroFlow
Internal medicine
medicine
neoplasias::neoplasias por tipo histológico::neoplasias de células plasmáticas::mieloma múltiple [ENFERMEDADES]
Humans
In patient
Survival rate
Multiple myeloma
Proportional hazards model
business.industry
Mieloma múltiple
Neoplasms::Neoplasms by Histologic Type::Neoplasms, Plasma Cell::Multiple Myeloma [DISEASES]
High-Throughput Nucleotide Sequencing
Hematology
Middle Aged
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Flow Cytometry
medicine.disease
Minimal residual disease
técnicas de investigación::técnicas genéticas::análisis de secuencias [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS]
Survival Rate
Transplantation
Investigative Techniques::Genetic Techniques::Sequence Analysis [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT]
Risk factors
Female
Multiple Myeloma
business
Follow-Up Studies
Subjects
Details
- Language :
- English
- ISSN :
- 20445385
- Database :
- OpenAIRE
- Journal :
- Blood Cancer Journal, Dipòsit Digital de Documents de la UAB, Universitat Autònoma de Barcelona, Scientia, Digital.CSIC. Repositorio Institucional del CSIC, instname, r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol, Blood Cancer Journal, Vol 10, Iss 10, Pp 1-10 (2020)
- Accession number :
- edsair.doi.dedup.....af0720a200412b5b1f4786e6828c750b